Each mL contains 30mg of diquafosol sodium.
<Precautions related to Indications>
This product should be used in patients diagnosed with dry eye, associated with keratoconjunctival epithelium disorders that accompany lacrimal fluid abnormality.
Patients with a history of hypersensitivity to any of the ingredients of this product.
Diquafosol sodium stimulated water and mucin secretion by acting on P2Y2 receptors on the conjunctival epithelial and goblet cell membrane and elevating intracellular calcium ion concentrations.
Repeated dose administration of diquafosol sodium 6 times daily for 4 weeks improved corneal epithelial damage in rat dry eye model in a dose-dependent manner, and exhibited the maximal effect at the concentration of 1% or higher. Repeated dose of 1% diquafosol sodium for 2 weeks exhibited the maximal improvement effect when daily administration exceeded 6 times.
If adverse reactions are observed, appropriate measures such as discontinuing administration should be taken.
|Incidence Type||Incidence unknown||≧5%||0.1 - < 5%|
|Ophthalmic||Corneal epithelium disorder (filamentary keratitis, keratitis superficial, corneal erosion, etc.) , conjunctivitis||Eye irritation||Eye discharge, conjunctival hyperaemia, eye pain, eye itching, foreign body sensation in eyes, visual discomfort, hyposphagma, abnormal sensation in eye (eyes dry feeling of, eye strange sensation of, sticky eye sensation), vision blurred, photophobia, lacrimation|
|Others||-||-||Headache, increased eosinophils, elevated ALT(GPT)|
Usually, instill 1 drop a time 6 times daily
Clear, colorless, sterile aqueous ophthalmic solution.
Keep below 30℃
Plastic bottle of 5 mL.
|Korea||DIQUAS® ophthalmic solution 3%|
|Thailand||DIQUAS® ophthalmic solution|
|Vietnam||DIQUAS® Dung dịch nhỏ mắt|
For healthcare professionals only. Full prescribing information is available on request.
For more information, please contact your local Santen office/representative.